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Background
Castleman disease was initially described as benign local-
ized lymph nodes found primarily in the mediastinum of
asymptomatic patients; additional types were recognized
that extend the spectrum of this heterogeneous group of
diseases. Optimal standard therapies have not been estab-
lished. Rituximab is an anti-CD20 monoclonal antibody
that has demonstrated efficacy in patients with various
lymphoid malignancies. It is an unusual complication in
patients with HIV-1 and HHV-8 infection, but it should be
included in the differential diagnosis of patients who
exhibit a relapsing systemic inflammatory syndrome and
lymphoadenopathy.
Methods
A 47 year-old patient, HIV seroconversion known since
1997, evaluated for the first time in 1997 (CD4 450) and
in 1999 (CD4 278). Up to 2006 follow-up was lost, but
receiving during two years antiretroviral treatment
(unknown). Re-evaluated again in October 2006 (CD4
75, viral load 290,000 copies/ml), and began treatment
with abacavir (ABC) + 3TC + efavirenz. In 15 days time he
presented systemic complaints of fever, weight loss and
night sweats. ABC was adjourned suspecting hypersensi-
tivity reaction. Also, he was diagnosed with splenic Non-
Hodgkin's lymphoma after splenectomy. Treatment was
re-initiated with 3TC + ddI + EFV. CT revealed pathologic
adenopathies in abdomen and armpits. During the fol-
lowing months similar symptoms recurred. A biopsy on
one of the cutaneous injuries led to findings characteristic
of Kaposi's sarcoma, and biopsy on armpit and abdomi-
nal lymph nodes of Castleman disease and infiltration by
Kaposi's sarcoma, and confirmed the presence of HHV-8.
After these diagnosis treatment with rituximab began
(375 mg/m2, 4 weekly doses).
Summary of results
After treatment the patient is asymptomatic (follow-up 7
months). Control CT, one month before finishing treat-
ment (CD4 140, undetectable CV), revealed multiple sub-
centimetric adenopathies in the abdominal tracking.
Conclusion
Rituximab has been an effective therapy in our patient,
without other chemotherapy treatments.
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